AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04506749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement consumption
Description: The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
Study NCT04506749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement consumption
Description: The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
Study NCT01279733 — intervention group
Intervention type: GENETIC
Intervention: Microarray analysis
Description: Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed.
Study NCT04247399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Description: Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
Study NCT00826163 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Budesonide
Description: Inhaled budesonide 400 mcg twice a day for 2 weeks
Study NCT00826163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled budesonide 400 mcg twice a day for 2 weeks
Study NCT02568579 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample/ stool sample
Description: blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
Study NCT03331185 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze Dried Bone Allograft
Description: Human derived bone particles used in oral and periodontal grafting procedures
Study NCT03331185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-PRF clot
Description: L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
Study NCT01294501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication administration educational module
Description: The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
Study NCT00977769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin 100 µg
Description: Hemodynamic effect of
Study NCT00977769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin 5 u
Description: Hemodynamic effect of
Study NCT00977769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (NaCl)
Description: Hemodynamic effect of
Study NCT04588818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab plus Methotrexate
Description: Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) .
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
Study NCT01709305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
Study NCT00014196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00014196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00014196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04444687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test for SARS-CoV-2
Description: * As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
Study NCT00308087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
Study NCT02626221 — intervention group
Intervention type: OTHER
Intervention: Non Interventional Study
Description: Non Interventional Study
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 1 mg
Description: 1 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 3 mg
Description: 3 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 10 mg
Description: 10 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 30 mg
Description: 30 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 120 mg
Description: 120 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 300 mg
Description: 300 mg IV every other wee
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 400 mg
Description: 400 mg IV every other wee
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 600 mg
Description: 600 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 800 mg
Description: 800 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 1200 mg
Description: 1200 mg IV every other week
Study NCT03219268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: margetuximab
Description: 15 mg/kg IV every 3 weeks
Study NCT04116528 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: 0.5mg/kg
Study NCT04116528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
Study NCT00626158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
Study NCT01073215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Lifestyle Modification
Description: The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
Study NCT04116528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Buprenorphine or Placebo orally dissolving tablet
Study NCT03254953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of body weight
Description: - weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
Study NCT03254953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of diet
Description: * track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm
Study NCT03254953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weekly personalized feedback + lessons + action plans
Description: - these are additional evidence-based intervention components
Study NCT03545373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin tablet taken orally
Study NCT03545373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin tablets taken orally
Study NCT03772951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
Study NCT03772951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine
Description: the course of disease is more than 2 years, the condition is stable for more than one month
Study NCT03772951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: the course of disease is more than 2 years, the condition is stable for more than one month
Study NCT04296474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard 5-grasses and birch
Description: Intralymphatic injections
Study NCT04296474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Description: intralymphatic injections
Study NCT03661034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (non-invasive, non-significant risk)
Description: Non-invasive, non-significant risk audio-visual sensory stimulation device
Study NCT04015115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Opioid Recovery Support service model
Description: see arm 1 description
Study NCT03697980 — intervention group
Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Study NCT00308087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
Study NCT01679236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Smokers
Description: The provides the Mindfulness Training for Smokers intervention (7 weeks long).
Study NCT01679236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Learning for Smokers
Description: This provides the Interactive Learning for Smokers intervention (7 weeks long).
Study NCT04221282 — intervention group
Intervention type: DRUG
Intervention: Zebinix
Description: ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
Study NCT02041247 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAC-3S
Description: VAC-3S is administered via intra-muscular route in the arm.
Study NCT02041247 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VAC-3S
Description: VAC-3S is administered via intra-muscular route in the arm.
Study NCT02835456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sharklet Catheter insertion
Study NCT02835456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Foley Catheter insertion
Study NCT01073215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Based Lifestyle Modification Program
Description: The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management.
Study NCT02706834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution
Study NCT00308087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
Study NCT01992653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at 375 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Study NCT03452384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
Study NCT03452384 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
Study NCT01053962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 0.3 mg
Description: SP-304 0.3 mg
Study NCT01053962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 1.0 mg
Description: SP-304 1.0 mg
Study NCT01053962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 3.0 mg
Description: SP-304 3.0 mg
Study NCT01053962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 9.0 mg
Description: SP-304 9.0 mg
Study NCT01053962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04476953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the study drug, but it contains no active ingredient.
Study NCT04476953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: \~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
Study NCT01469832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: * Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells
Study NCT02706834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution
Study NCT04427163 — intervention group
Intervention type: GENETIC
Intervention: Blood sample analysis
Description: Nucleic acids sequencing, presence of proteins and metabolites.
Study NCT04427163 — intervention group
Intervention type: OTHER
Intervention: Health status
Description: Health status will be examined by a physician and subject will complete a health status questionnaire.
Study NCT04427163 — intervention group
Intervention type: OTHER
Intervention: Race and ethnicity
Description: Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
Study NCT02713269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02713269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02713269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02713269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo CT-guided SSRS
Study NCT02713269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation Therapy
Description: Undergo thermal ablation therapy